Clinical study
MP101-1001
MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
| Status | Recruiting |
|---|---|
| Type | Trial |
| Countries | South Korea |
| Conditions studied | Pneumonia - Bacterial; Pseudomonas Aeruginosa Infection |
| Study years | 2026–2026 (estimated) |
| Entry review | 2026-10-03 |
Participation
Check the study record or contact the study team for current recruitment and eligibility.
Study eligibility
Inclusion Criteria: * Subjects aged 19 years or older. * Clinical diagnosis of acute pneumonia with radiologic evidence of pulmonary infiltrates. * Confirmed Pseudomonas aeruginosa (PA) infection via valid respiratory specimens. * PA isolate demonstrates susceptibility to MP101 and non-susceptibility to current antibiotic therapy. * Adequate organ function as defined by hematological, hepatic, and renal laboratory parameters . Exclusion Criteria: * Persistent septic shock or hemodynamically unstable condition. * Active pulmonary tuberculosis or non-bacterial pneumonia. * Significant pleural effusion or lung abscess requiring therapeutic drainage. * Clinically significant cardiovascular, hepatic, or renal impairment . * Immunocompromised status or hematological malignancies. * Known hypersensitivity to bacteriophages, study components, or concomitant antibiotics. * Participation in another clinical trial within 30 days prior to screening. * Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study.
Study description
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia. The study will also assess the pharmacokinetic and pharmacodynamic characteristics of MP101 and its antibacterial activity, including changes in P. aeruginosa burden in sputum and changes in susceptibility to MP101 and concomitant antibiotics.
Study registrations
| ClinicalTrials.gov | NCT07492771 |
|---|
Recorded study locations (1)
Locations listed in the study record; this does not confirm current recruitment or treatment outside the study. A site label may be older than the overall study status.
Severance Hospital
Seoul, Seodaemun-gu, South Korea
Recorded site status: Recruiting. Study location source ↗
Related programs(2)
MicrobiotiX Co Ltd
Research/development
Recorded program–study link. Website
Severance Hospital — MP101 pneumonia trial
Official referral/inquiry route
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Study ID | nct07492771 |
|---|